ASX:MSBMesoblast Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mesoblast limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$1.34 -0.12 (-8.19 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's RangeA$1.32Now: A$1.35▼A$1.5050-Day RangeA$1.10MA: A$1.98▼A$2.9252-Week RangeA$1.02Now: A$1.35▼A$3.21Volume4.48 million shsAverage Volume2.19 million shsMarket Capitalization$721.97 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartEarningsInsider TradesHeadlinesOptions Chain Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Mesoblast. Previous Next 2.1 Community Rank Outperform VotesMesoblast has received 64 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMesoblast has received 88 “underperform” votes. (Add your “underperform” vote.)Community SentimentMesoblast has received 57.89% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote “Outperform” if you believe MSB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MSB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mesoblast are expected to decrease by -100.00% in the coming year, from A($0.04) to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioMesoblast has a PEG Ratio of 20.71. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.42 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:MSB Previous Symbol CUSIPN/A CIKN/A Webhttp://www.mesoblast.com/ Phone+61-3-96396036Debt Debt-to-Equity Ratio18.83 Current Ratio1.21 Quick Ratio1.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth20.71 Sales & Book Value Annual Sales$22.47 million Price / Sales32.13 Cash FlowA$0.16 per share Price / Cash Flow8.55 Book ValueA$0.94 per share Price / Book1.44Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees81 Outstanding Shares536,779,008Market Cap$721.97 million Next Earnings Date5/29/2020 (Estimated) OptionableOptionable Receive MSB News and Ratings via Email Sign-up to receive the latest news and ratings for MSB and its competitors with MarketBeat's FREE daily newsletter. Mesoblast (ASX:MSB) Frequently Asked Questions How has Mesoblast's stock been impacted by COVID-19 (Coronavirus)? Mesoblast's stock was trading at A$1.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MSB stock has decreased by 25.7% and is now trading at A$1.35. View which stocks have been mosted impacted by Coronavirus. When is Mesoblast's next earnings date? Mesoblast is scheduled to release its next quarterly earnings announcement on Friday, May 29th 2020. View our earnings forecast for Mesoblast. How were Mesoblast's earnings last quarter? Mesoblast limited (ASX:MSB) announced its quarterly earnings data on Thursday, February, 21st. The company reported ($0.09) EPS for the quarter. View Mesoblast's earnings history. Has Mesoblast been receiving favorable news coverage? Press coverage about MSB stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mesoblast earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMesoblast. Who are some of Mesoblast's key competitors? Some companies that are related to Mesoblast include MorphoSys (MOR), Cronos Group (CRON), Abcam (ABC), Genus (GNS), Kodiak Sciences (KOD), Concordia International (CXR), Polynovo (PNV), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Bellus Health (BLU), Oxford BioMedica (OXB), Trillium Therapeutics (TRIL), Biotest (BIO), CEL-SCI (CVM) and Cel-Sci (CVM). What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Mesoblast (MESO), Alliance Resource Partners (ARLP), OceanaGold (OGC), Bubs Australia (BUB), Starpharma (SPL), GENFIT S A/ADR (GNFT), Portola Pharmaceuticals (PTLA), Viking Therapeutics (VKTX), Immutep (IMM) and Evolution Mining (EVN). Who are Mesoblast's key executives? Mesoblast's management team includes the following people: Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)Mr. Roger D. Brown BA, Head of Spinal Orthopedic DisordersMr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)Dr. Kenneth M. Borow M.D., Exec. (Age 71) What is Mesoblast's stock symbol? Mesoblast trades on the ASX under the ticker symbol "MSB." What is Mesoblast's stock price today? One share of MSB stock can currently be purchased for approximately A$1.35. How big of a company is Mesoblast? Mesoblast has a market capitalization of $721.97 million and generates $22.47 million in revenue each year. Mesoblast employs 81 workers across the globe. View additional information about Mesoblast. What is Mesoblast's official website? The official website for Mesoblast is http://www.mesoblast.com/. How can I contact Mesoblast? Mesoblast's mailing address is L 38 55 Collins St, MELBOURNE, VIC 3000, Australia. The company can be reached via phone at +61-3-96396036. This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: What is the definition of a trade war?
